Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | BCL9 | O00512 | 3/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526441 | 0.85 | CACNA1B (0.54) | CACNA1BCHRM4 | |
| SCHEMBL6932398 | 0.77 | CACNA1B (0.42) | CACNA1BGPBAR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4489454 | 0.75 | CACNA1B (0.46) | CACNA1BSMN1; SMN2 | |
| SCHEMBL7528367 | 0.73 | CACNA1B (0.61) | CACNA1B | |
| SCHEMBL4502898 | 0.73 | CACNA1B (0.81) | CACNA1B | |
| SCHEMBL7527934 | 0.73 | CACNA1B (0.64) | CACNA1B | |
| SCHEMBL7528379 | 0.72 | CACNA1B (0.69) | CACNA1B | |
| SCHEMBL5415124 | 0.71 | CHRM4 (0.35) | CACNA1BCHRM4BCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL5405612 | 0.71 | CHRM4 (0.35) | CACNA1BCHRM4BCL9CTNNB1SMN1; SMN2 | |
| SCHEMBL7532861 | 0.71 | CACNA1B (0.59) | CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | CACNA1B 1/4885CHRM4 1397/4885BCL9 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.